Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from A call for cytomegalovirus stewardship initiatives in cardiothoracic transplant. Local targets link to admitted publications; unresolved targets remain external evidence.
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
10.1097/tp.0000000000002191 · 2018 · External reference
Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
10.1111/ctr.13512 · 2019 · External reference
Ganciclovir-resistant cytomegalovirus infection in abdominal solid organ transplant recipients: case series and review of the literature
10.1002/phar.1987 · 2017 · External reference
Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis
10.1001/jama.1989.03420240075030 · 1989 · External reference
Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function
2004 · External reference
The association between cytomegalovirus infection and cardiac allograft vasculopathy in the era of antiviral valganciclovir prophylaxis
10.1097/tp.0000000000003015 · 2020 · External reference
High incidence of cy -tomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis
10.1016/j.healun.2008.02.002 · 2008 · External reference
Cytomegalovirus infection in heart transplantation: a single center experience
10.1111/tid.12896 · 2018 · External reference
Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis
10.1111/ctr.12686 · 2016 · External reference
Cytomegalovirus infection is associated with development of chronic lung allograft dysfunction
10.1007/s00408-022-00551-0 · 2022 · External reference
Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial
10.7326/0003-4819-152-12-201006150-00003 · 2010 · External reference
Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: a retrospective study
10.1111/tid.13277 · 2020 · External reference
Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients
10.1111/tid.13015 · 2019 · External reference
Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients
10.1111/tid.12964 · 2018 · External reference
Cytomegalovirus antiviral stewardship in solid organ transplant recipients: a new gold standard
10.1111/tid.13864 · 2022 · External reference
Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients
10.1016/s1053-2498(02)00463-1 · 2002 · External reference
High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy
10.1086/338143 · 2002 · External reference
Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens
10.1128/aac.00561-13 · 2014 · External reference
The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients
10.1017/ice.2020.203 · 2020 · External reference
Cytomegalovirus antiviral stewardship in the COVID-19 Era: Increasing complexity of prophylaxis and treatment and potential mitigation strategies
10.1111/tid.13586 · 2021 · External reference
Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: a paired kidney analysis
10.1111/ajt.15183 · 2019 · External reference
Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients
10.1111/j.1600-6143.2009.02618.x · 2009 · External reference
Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study
10.1093/cid/cis993 · 2013 · External reference
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match
10.1016/j.healun.2019.08.004 · 2019 · External reference
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match
10.1016/j.healun.2019.08.001 · 2019 · External reference
Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: a meta-analysis
10.1016/j.ijcard.2018.03.111 · 2018 · External reference
Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation
10.1016/j.healun.2013.04.010 · 2013 · External reference
mTOR regulates memory CD8 T-cell differentiation
10.1038/nature08155 · 2009 · External reference
Mycophenolate Mofetil Cardiac Study Investigators. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients
10.1016/j.healun.2005.02.002 · 2005 · External reference
High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after completion of 3 months of valganciclovir prophylaxis
10.1016/j.healun.2008.02.002 · 2008 · External reference
Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy
10.1016/j.healun.2009.03.012 · 2009 · External reference
Letermovir for cytomegalovirus prophylaxis in high risk heart transplant recipients
10.1111/ctr.14808 · 2022 · External reference
Cytomegalovirus prevention in thoracic organ transplantation: a single-center evaluation of letermovir prophylaxis
10.1016/j.healun.2021.12.005 · 2022 · External reference
Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients
10.1111/tid.13166 · 2019 · External reference
Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients
10.1016/j.healun.2009.02.009 · 2009 · External reference
Detection of human cytomegalovirus antigenemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients
10.1136/thx.50.1.9 · 1995 · External reference
Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients
10.1016/s1053-2498(00)00070-x · 2000 · External reference
Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients
10.1016/s1053-2498(01)00283-2 · 2001 · External reference
Assessment of cytomegalovirus hybrid preventative strategy in pediatric heart transplant patients
10.1093/jpids/pis056 · 2012 · External reference
Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients
10.3851/imp1879 · 2011 · External reference
Safety and efficacy of letermovir vs valganciclovir for prevention of cytomegalovirus disease in CMV high-risk D+/R- kidney transplant recipients: a phase 3 randomized study. Presented at IDWeek 2022, Oct 19-23, Washington DC, USA
2022 · External reference
Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity
10.1111/tid.13766 · 2022 · External reference
An international survey of cytomegalovirus management practices in lung transplantation
10.1097/tp.0b013e3181ea3955 · 2010 · External reference
Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival
2020 · External reference
Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation
10.1111/tid.13617 · 2021 · External reference
Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients
10.1093/clinids/10.supplement_3.s563 · 1988 · External reference
Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial
10.1093/cid/ciab988 · 2022 · External reference
Maribavir for the management of cytomegalovirus in adult transplant recipients: a review of the literature and practical considerations
2023 · External reference
Real world experience with Maribavir for the treatment of cytomegalovirus in solid organ transplant recipients
10.1111/ctr.14929 · 2023 · External reference
Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease
10.1016/j.intimp.2004.09.006 · 2005 · External reference
The use of CMVIg rescue therapy in cardiothoracic transplantation: a single-center experience over 6 years (2011-2017)
10.1111/ctr.13655 · 2019 · External reference
Management of ganciclovir resistant cytomegalovirus retinitis in a solid organ transplant recipient: a review of current evidence and treatment approaches
10.1080/09273948.2019.1645188 · 2020 · External reference
Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review
10.1111/tid.13733 · 2022 · External reference
Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial
10.1093/cid/ciy549 · 2019 · External reference
Use of T cell mediated immune functional assays for adjustment of immunosuppressive or anti-infective agents in solid organ transplant recipients: a systematic review
10.3389/fimmu.2020.567715 · 2020 · External reference
Monitoring of cytomegalovirus (CMV)-specific cell-mediated immunity in heart transplant recipients: clinical utility of the QuantiFERON-CMV assay for management of posttransplant CMV infection
10.1128/jcm.01040-17 · 2018 · External reference
QuantiFERON-CMV guided virostatic prophylaxis after heart transplantation
10.1016/j.healun.2020.01.001 · 2020 · External reference
A randomized study of Quantiferon CMV-directed versus fixed-duration valganciclovir prophylaxis to reduce late CMV after lung transplantation
10.1097/tp.0000000000002454 · 2019 · External reference
Association of CMV-specific T-cell immunity and risk of CMV infection in lung transplant recipients
10.1111/ctr.14294 · 2021 · External reference
Pretransplant cytomegalovirus-specific cellular immunity and risk of viral reactivation following lung transplantation: a prospective cohort study
10.1093/infdis/jiaa750 · 2021 · External reference
CMV-specific cell-mediated immunity predicts a high level of CMV replication after prophylaxis withdrawal in lung transplant recipients
10.1093/infdis/jiaa727 · 2021 · External reference
An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation
10.1111/ajt.14347 · 2017 · External reference
Cytomegalovirus immunity assays predict viremia but not replication within the lung allograft
10.1097/txd.0000000000001501 · 2023 · External reference
Efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis to prevent cytomegalovirus disease in lung transplant recipients (CYTOCOR STUDY): an open-label, randomised, non-inferiority clinical trial
10.1136/bmjopen-2019-030648 · 2019 · External reference
Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: is there a "Safe Corridor" after kidney transplantation?
10.1111/tid.13489 · 2021 · External reference
Factors related to the development of CMV-specific CD8+ T cell response in CMV-seropositive solid organ transplant candidates
10.1111/ajt.13012 · 2015 · External reference
Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients
10.3851/imp1879 · 2011 · External reference
Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients
10.1016/j.healun.2022.05.004 · 2022 · External reference
Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?
10.1111/j.1399-0012.2007.00778.x · 2008 · External reference
